Quintiles will bring its clinical trial services to a global consortium supported in part by the Bill & Melinda Gates Foundation aimed at bringing new, affordable medicines to the world’s poorest countries.
Durham, North Carolina-based Quintiles has been selected as a preferred provider to 14 Product Development Partnerships, or PDPs — nonprofit entities that work to develop new drugs for underserved patient populations. The PDP model is largely one of outsourced drug development, from R&D through clinical trials. One example of a PDP is the Medicines for Malaria Venture, a Switzerland-based public-private partnership working for the discovery and development of new, affordable antimalarial medicines.
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Besides the Gates Foundation, the PDPs receive funding from government agencies and private sources. Financial terms of Quintiles involvement were not disclosed. But the clinical research organization said that the consortium of 14 PDPs expect to fund 128 clinical trials over the next two years. Those drug candidates will have access to the global drug-testing infrastructure of Quintiles, particularly in the areas of infectious diseases such as HIV, malaria and tuberculosis. Quintiles employs more than 20,000 people in 60 countries.
Dr. Kelly McKee, Quintiles vice president and managing director, public health and government services, said in a statement that the PDPs work holds promise for helping patients worldwide.
“The work they’re doing has the potential to reshape global health within a generation,” McKee said. “The public health issues on which they are focused has the potential to save millions of lives.”